Summary
Nathaniel Mahieu is a Ph.D. scientist and team leader with 11 years of experience building and scaling mass spectrometry-driven metabolomics, proteomics, and chemoproteomics platforms for discovery and commercialization. He has led multi-disciplinary teams at Flagship/Spinup and Empress Therapeutics, turning complex wet-lab workflows into automated, production-grade pipelines that pair high-resolution instrumentation with cloud-enabled data infrastructure. Nathaniel combines hands-on expertise across Orbitrap/QTOF platforms, Nextflow/Docker-based pipelines, and R-driven analysis with a knack for translating methods into commercial products and partnerships. An active seed investor and advisor, he seeks ventures that connect rigorous science to community impact—an angle shaped by early work commercializing a credentialing kit and by algorithmic projects recovering DNA adducts from WSIM-MS2 data. Based in Cambridge, MA, he blends deep technical craft with venture-minded leadership to move possibilities into meaningful outcomes.
12 years of coding experience
15 years of employment as a software developer
PhD, Chemistry, PhD, Chemistry at Washington University in St. Louis
University of Missouri